Hans Gelderblom

Hans Gelderblom

Leiden University - Leiden / Netherlands
Others
AD Scientific Index ID: 4684880
Universiteit Leiden
person_outline Hans Gelderblom's MOST POPULAR ARTICLES
1-) Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial A Grothey, E Van Cutsem, A Sobrero, S Siena, A Falcone, M Ychou, ... The Lancet 381 (9863), 303-312, 2013 25782013
2-) Pazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomised, double-blind, placebo-controlled phase 3 trialWTA Van Der Graaf, JY Blay, SP Chawla, DW Kim, B Bui-Nguyen, ...The Lancet 379 (9829), 1879-1886, 201220232012
3-) Cremophor EL: the drawbacks and advantages of vehicle selection for drug formulationH Gelderblom, J Verweij, K Nooter, A SparreboomEuropean journal of cancer 37 (13), 1590-1598, 200120132001
4-) Efficacy and safety of regorafenib for advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib (GRID): an international, multicentre, randomised …GD Demetri, P Reichardt, YK Kang, JY Blay, P Rutkowski, H Gelderblom, ...The Lancet 381 (9863), 295-302, 201315402013
5-) Doxorubicin alone versus intensified doxorubicin plus ifosfamide for first-line treatment of advanced or metastatic soft-tissue sarcoma: a randomised controlled phase 3 trialI Judson, J Verweij, H Gelderblom, JT Hartmann, P Schöffski, JY Blay, ...The lancet oncology 15 (4), 415-423, 201410542014